Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita-shi, Osaka 565-0871, Japan.
Br J Cancer. 2012 Feb 28;106(5):947-54. doi: 10.1038/bjc.2012.35. Epub 2012 Feb 14.
Recently, PFTK1 was identified as a member of the cyclin-dependent kinase family; however, its expression and clinical significance in oesophageal squamous cell carcinoma (ESCC) have not been evaluated.
PFTK1 expression was initially examined by expression microarray in 77 ESCC patients. Using independent samples of 223 patients, PFTK1 expression was evaluated immunohistochemically to assess the relationship between expression and various clinicopathological parameters. The association between PFTK1 and the response to chemotherapy was also investigated in pretreatment samples of 85 patients who received chemotherapy as first treatment.
Significant upregulation of PFTK1 expression was noted in ESCC compared with normal epithelium. PFTK1 expression was positive in 51.6% (115 out of 223) of the tumours, but did not correlate with any clinicopathological parameter. The 5-year overall survival rate was poorer in patients positive for PFTK1 (43.6%) than those with negative expression (66.2%, P<0.001). Uni- and multivariate analyses identified PFTK1 as an independent marker of prognosis (RR=2.428, 95% CI=1.615-3.711, P<0.001). Out of 85 biopsy samples, 40 (47.1%) tumours showed PFTK1-positive expression, and the response rate to chemotherapy was significantly lower than PFTK1-negative tumours (27.9% vs 72.1%, P<0.001).
PFTK1 is not only useful as a prognostic marker, but also as a predictor of the response to chemotherapy.
最近，PFTK1 被鉴定为细胞周期蛋白依赖性激酶家族的成员；然而，其在食管鳞状细胞癌（ESCC）中的表达和临床意义尚未得到评估。
通过在 77 例 ESCC 患者中进行表达微阵列初步检查 PFTK1 的表达。使用 223 例患者的独立样本，通过免疫组织化学评估 PFTK1 表达，以评估表达与各种临床病理参数之间的关系。还在 85 例接受化疗作为一线治疗的患者的预处理样本中研究了 PFTK1 与化疗反应之间的关系。
与正常上皮相比，ESCC 中明显上调了 PFTK1 的表达。在 223 例肿瘤中，PFTK1 表达阳性率为 51.6%（115/223），但与任何临床病理参数均无关。PFTK1 阳性患者的 5 年总生存率（43.6%）明显低于 PFTK1 阴性患者（66.2%，P<0.001）。单因素和多因素分析均将 PFTK1 确定为独立的预后标志物（RR=2.428，95%CI=1.615-3.711，P<0.001）。在 85 个活检样本中，40 个（47.1%）肿瘤显示 PFTK1 阳性表达，化疗反应率明显低于 PFTK1 阴性肿瘤（27.9%比 72.1%，P<0.001）。
PFTK1 不仅是一种有用的预后标志物，也是化疗反应的预测因子。
Zotero 插件
